Loading
Cell therapy engineer whose CAR-TEAM cells produced rapid regressions of recurrent glioblastoma.
Marcela Maus leads a laboratory that engineers CAR T cells to overcome the barriers of solid tumours, including the CARv3-TEAM-E cells that secrete a T-cell-engaging antibody against EGFR and produced dramatic, if transient, radiographic regressions in recurrent glioblastoma in a 2024 first-in-human trial. She previously led the first EGFRvIII CAR-T trial at Penn and directs cellular immunotherapy at MGH.
| Title | Journal | Year |
|---|---|---|
| Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma | NEJM | 2024 |
| A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma | Science Translational Medicine | 2017 |
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy and the tags cell-therapy, car-t.
Shares Science Translational Medicine, CAR-T cell therapy and the tags cell-therapy, car-t.
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy, Glioma & glioblastoma.
Shares CAR-T cell therapy and the tags cell-therapy, car-t.
Shares CAR-T cell therapy and the tags cell-therapy, car-t.
Shares CAR-T cell therapy and the tags cell-therapy, car-t.
Shares Massachusetts General Hospital Cancer Center, CAR-T cell therapy and the tag car-t.
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.